Cannabis company Creso Pharma (OTCMKTS: COPHF)’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early findings on its ongoing Phase 2 clinical trial assessing the efficacy of psilocybin on treatment-resistant PTSD.
The single-arm, open-lab study tests the efficacy of Halucenex’s synthetic psilocybin aqueous solution, Lucenex, in both 10mg and 25mg formats on severe PTSD symptoms of 20 patients.
The psychedelic is being administered in separate sessions in a microdose and macro dose format.
Severe PTSD symptoms measured are depression and anxiety. Other measures include sleep time, addiction severity, suicidal ideation, general psychological symptoms such as pain and interpersonal relationships, overall functioning, work capacity, and physiological measures such as weight and blood pressure.
Of the total participants, two patients to date …